<DOC>
	<DOCNO>NCT02163421</DOCNO>
	<brief_summary>The purpose study ass absolute bioavailability pharmacokinetics vedolizumab follow single injection vedolizumab subcutaneously 3 vary dos .</brief_summary>
	<brief_title>Bioavailability Pharmacokinetics Vedolizumab Healthy Participants Following Single Subcutaneous Administration</brief_title>
	<detailed_description>The drug test study call vedolizumab . Vedolizumab test determine bioavailability , safety , tolerability body three vary dos vedolizumab SC compare people administer vedolizumab IV . The study enroll approximately 24 non-Japanese patient 24 Japanese patient . Participants randomly assign one four treatment group : - Vedolizumab Intravenous 300 mg - Vedolizumab Subcutaneous 54 mg - Vedolizumab Subcutaneous 108 mg - Vedolizumab Subcutaneous 160 mg All participant receive treatment assign Day 1 study . This single-center trial conduct United Kingdom . The overall time participate study 196 day . Participants make 10 visit clinic , include one 8 day period confinement clinic , contact telephone Study Day 168 ( +/-3 ) , approximately 6 month dose follow-up questionnaire .</detailed_description>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is healthy male female adult nonJapanese decent 18 60 year age inclusive Japanese descent ( bear Japanese parent grandparent live outside Japan le 5 year ) , 20 60 year age inclusive , time informed consent . 4 . Weighs least 45 kg ( 99 lb ) body mass index ( BMI ) 18.0 30.0 kg/m^2 nonJapanese participant 18.0 28.0 kg/m^2 Japanese participant , inclusive Screening . 5 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study minimum 18 week last dose . 6 . A female participant childbearing potential sexually active nonsterilized male partner agree use acceptable method contraception signing inform consent throughout duration study minimum 18 week last dose . 1 . Has receive investigational compound within 30 day prior dose study medication history treatment another monoclonal antibody within 6 month dose study medication . 2 . Has receive vedolizumab previous clinical study therapeutic agent . 3 . Is immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Has uncontrolled , clinically significant ( CS ) neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , immunologic , endocrine disease , psychiatric disorder , abnormality , may impact ability participant potentially confound study result . 5 . Has know hypersensitivity component formulation vedolizumab SC vedolizumab IV . 6 . Has one positive response progressive multifocal leukoencephalitis ( PML ) subjective symptom checklist screen dose Day 1 . 7 . Has positive result drug abuse alcohol Screening Check ( Day 1 ) . 8 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior Screening visit unwilling agree abstain alcohol 48 hr prior Day 1 throughout confinement 48 hr prior clinic visit drug throughout study . 9 . Is pregnant lactate intend become pregnant , , within 18 week last dose study ; intend donate ova time period . 10 . If male , participant intend donate sperm course study 18 week last dose study . 11 . Has evidence current cardiovascular , central nervous system , hepatic , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma hypoxemia , hypertension , seizure , allergic skin rash . There find participant 's medical history , physical examination , safety laboratory test give reasonable suspicion disease would contraindicate take vedolizumab , similar drug class , might interfere conduct study . This include , limited , peptic ulcer disease , seizure disorder , cardiac arrhythmia . 12 . Had surgical procedure require general anesthesia within 30 day initial Screening Visit , plan undergo surgery require general anesthesia study period Final Visit Day 127 . 13 . Has history cancer , except basal cell carcinoma remission least 5 year prior Day 1 . 14 . Participant unable attend study day comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>